Novel Iron Compound Patented in Japan

Triferic, an investigational drug, is delivered to hemodialysis patients via dialysate.
Triferic, an investigational drug, is delivered to hemodialysis patients via dialysate.

Rockwell Medical, Inc., of Wixom, Mich., has received a Japanese patent for its investigational iron-delivery compound soluble ferric pyrophosphate (SFP), which the company is marketing under the name Triferic.

The product is a unique iron compound delivered to iron-deficient hemodialysis patients via dialysate, replacing the 5-7 mg of iron lost during dialysis treatments. Once in the dialysate, SFP crosses the dialyzer membrane and enters the bloodstream, where it immediately binds to transferrin and is delivered to the bone marrow, similar to the way dietary iron is processed in the human body.

The patent covers the synthesis and formulation of SFP and provides protection through July 18, 2028.

Clinical trials have demonstrated at SFP safely maintains hemoglobin levels without increasing iron stores and significantly reduces requirements of erythropoiesis-stimulating agents.

Last September, the FDA accepted Triferic as the proprietary trade name for SFP.

Loading links....
You must be a registered member of Renal and Urology News to post a comment.